Notice of Intent- 1250278 llumina.docx

Food and Drug Administration (FDA)

Notice of Intent to Sole Source

Subject: Sole Source Fixed Price Contract for the procurement of Reagent Chemistry Kits to Illumina Inc., under Request for Quote FDA-RFQ-22-1250278.

Notice of Intent to Sole Source to: Illumina Inc.

Pursuant to the authority of 41 USC 3304(a)(1), as implemented by Federal Acquisition Regulation (FAR) Subpart 6.302-1, (there is only one responsible source and no other supplies or services will satisfy agency requirements), the Food and Drug Administration (FDA) intends to award a Sole Source IDIQ to Illumina Inc., located at:

Illumina, Inc.

5200 Illumina Way San Diego, CA 92122 USA tel 858.202.4500 www.illumina.com

FDA has a requirement to procure Reagent Chemistry Kits to Illumina., under Request for Quote FDA-RFQ-22-1250278 as a sole source acquisition.

Illumina Inc., is the sole manufacturer and the only source which provides the Reagent Chemistry Kits required. Illumina has not authorized any third party intermediary to provide Illumina products for the Reagent Chemistry kits.

The NAICS Code for this procurement is: 334516 - Analytical Laboratory Instrument Manufacturing

This notice is not a request for competitive proposals. However, any party that believes it is capable of meeting this requirement as stated herein may submit a written capability statement that clearly supports and demonstrates their ability to perform the requirement. Capability statements must be received by the response date and time of this notice. Submissions will be reviewed to determine if they can meet the requirement. A determination by the Government to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government.

It is anticipated that an award will be issued to Illumina Inc., within approximately fifteen (15) days after the date of this notice unless the Government determines that any other organization has the capacity to meet this requirement.

Response Date: 10:00 a.m. EST 4/28/2022. Please email responses to Nina Montgomery at Nina.Montgomery@fda.hhs.gov image1.png